<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><atom:link href="https://www.oncologynewscentral.com/feed" rel="self" type="application/rss+xml" /><title><![CDATA[ONC]]></title><description><![CDATA[The Latest on ONC]]></description><link>https://www.oncologynewscentral.com</link><image><url>https://www.oncologynewscentral.com/favicon-512.png</url><title>ONC</title><link>https://www.oncologynewscentral.com</link></image><generator>RSS for Node</generator><lastBuildDate>Sat, 16 May 2026 21:58:08 GMT</lastBuildDate><language><![CDATA[en]]></language><item><title><![CDATA[Oncology News Central]]></title><description><![CDATA[Oncology News Central]]></description><link>https://www.oncologynewscentral.com/</link><guid isPermaLink="true">https://www.oncologynewscentral.com/</guid><pubDate>Fri, 15 May 2026 11:00:46 GMT</pubDate></item><item><title><![CDATA[SCLC Treatment Paradigm Is Challenging, Changing]]></title><description><![CDATA[So Yeon Kim, MD, discusses the growing shift in SCLC care toward multiline and multimodality treatment strategies, the emergence of DLL3-targeted therapies, and more.]]></description><link>https://www.oncologynewscentral.com/sclc/inside-the-challenging-changing-treatment-paradigm-for-small-cell-lung-cancer</link><guid isPermaLink="true">https://www.oncologynewscentral.com/sclc/inside-the-challenging-changing-treatment-paradigm-for-small-cell-lung-cancer</guid><pubDate>Fri, 15 May 2026 10:51:24 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/4K9xAQWzhQ2ZAMr77O9WL/f4bc5356bfa4543f5919cb7fa8e43a90/GettyImages-1906998196-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Bispecific Model “Adapted Easily” at Cancer Clinics]]></title><description><![CDATA[Delivering bispecific T-cell engager therapy locally in rural cancer centers is feasible and reduces the burden of long travel for treatment on patients, experts suggest.]]></description><link>https://www.oncologynewscentral.com/oncology/bispecific-delivery-model-can-be-adapted-easily-at-cancer-clinics-experts-say</link><guid isPermaLink="true">https://www.oncologynewscentral.com/oncology/bispecific-delivery-model-can-be-adapted-easily-at-cancer-clinics-experts-say</guid><pubDate>Fri, 15 May 2026 10:37:18 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/49ewVUycKiqngLqFLRAoRd/ffc079b18a6ee4b43ff55317639290a5/GettyImages-1500551921-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Community Oncology Alliance]]></title><description><![CDATA[Serving as the voice of community oncology in Washington, DC, and across the country, the Community Oncology Alliance (COA) aims to improve patient care, offer professional growth for cancer care providers, and support practice operations. Individuals from every level of the cancer care delivery team, including oncologists, hematologists, pharmacists, oncology nurses and nurse practitioners, physician assistants, patients, and survivors, volunteer their time to lead COA and serve on its committees.]]></description><link>https://www.oncologynewscentral.com/partners/community-oncology-alliance</link><guid isPermaLink="true">https://www.oncologynewscentral.com/partners/community-oncology-alliance</guid><pubDate>Thu, 14 May 2026 11:19:39 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/1c009fP6ltZNjd7CwayWRI/f17c385764d49d6547d58da54f660a3a/COA_seal_2019-4C_HighRes.png?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Community Cancer Practices Must “Pick the Right Tool”]]></title><description><![CDATA[AI and other technology advances offer many advantages for community oncology practices, but being selective is important, says John Sargent, MD, MSt.]]></description><link>https://www.oncologynewscentral.com/video/oncology/as-technology-advances-explode-community-cancer-practices-must-pick-the-right-tool</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/oncology/as-technology-advances-explode-community-cancer-practices-must-pick-the-right-tool</guid><pubDate>Thu, 14 May 2026 10:54:31 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/4hoF2dWmglgWj6PYnGA0lk/71a1fc347a6b071d7dbeff4b0d450683/Sargent-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[FDA Approves All-Oral AML Combo for Older Adults]]></title><description><![CDATA[The FDA approved the all-oral combination of decitabine, cedazuridine (Inqovi), and venetoclax (Venclexta) for adults aged 75 years and older with newly diagnosed acute myeloid leukemia.]]></description><link>https://www.oncologynewscentral.com/drugs/info/fda-approves-oral-combination-for-older-adults-with-acute-myeloid-leukemia</link><guid isPermaLink="true">https://www.oncologynewscentral.com/drugs/info/fda-approves-oral-combination-for-older-adults-with-acute-myeloid-leukemia</guid><pubDate>Thu, 14 May 2026 10:34:34 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/qnUR09t0247wS0UJeVKE0/44f11406b52aebc7cb36c6f8b8b65d91/custom_thumbnail_large.png?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[FDA Approves Sonrotoclax for Mantle Cell Lymphoma]]></title><description><![CDATA[The FDA granted accelerated approval to sonrotoclax (Beqalzi) for relapsed or refractory mantle cell lymphoma after at least two lines of therapy.]]></description><link>https://www.oncologynewscentral.com/drugs/info/fda-approves-sonrotoclax-for-mantle-cell-lymphoma</link><guid isPermaLink="true">https://www.oncologynewscentral.com/drugs/info/fda-approves-sonrotoclax-for-mantle-cell-lymphoma</guid><pubDate>Thu, 14 May 2026 10:23:48 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/3mu0dB2XHUtaL0GolYS6H4/fbe87424d5637a271ad4c3c374f6b383/custom_thumbnail_large.png?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[What Makes Outpatient CAR-T Such a “Heavy Lift”?]]></title><description><![CDATA[“The process of starting an all-outpatient CAR-T therapy has been a very heavy lift,” said Katie Alexander, MSN, APRN-CNP, AOCNP. She described some of the biggest hurdles.]]></description><link>https://www.oncologynewscentral.com/video/oncology/implementing-outpatient-car-t-can-be-a-very-heavy-lift</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/oncology/implementing-outpatient-car-t-can-be-a-very-heavy-lift</guid><pubDate>Wed, 13 May 2026 18:25:17 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/aR7EI6zwoYUWjj3pZOnCj/d9bfbf2247da3a947c7b8b0baf8a22a6/Alexander-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Implementing Cell Therapy in Community Oncology]]></title><description><![CDATA[Implementing CAR-T therapy programs in community oncology settings comes with various challenges, explains Michael T. Byrne, DO. He offers advice and insights.]]></description><link>https://www.oncologynewscentral.com/video/oncology/implementing-cell-therapy-in-community-oncology</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/oncology/implementing-cell-therapy-in-community-oncology</guid><pubDate>Wed, 13 May 2026 10:26:21 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/7ahI2vu2OcNktrjfaz7Vdi/498a91c00fcbbd2761d4de0352fb8b8b/large-Byrne-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Tazemetostat Withdrawn Over Malignancy Concerns]]></title><description><![CDATA[Tazemetostat (Tazverik) was voluntarily withdrawn for follicular lymphoma and epithelioid sarcoma due to the risk for hematologic second primary malignancies.]]></description><link>https://www.oncologynewscentral.com/drugs/info/tazemetostat-withdrawn-over-secondary-primary-cancer-risk</link><guid isPermaLink="true">https://www.oncologynewscentral.com/drugs/info/tazemetostat-withdrawn-over-secondary-primary-cancer-risk</guid><pubDate>Tue, 12 May 2026 15:05:18 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/3U9FvqsV1tW9eCsUqmJLlV/e5891c1c82368f5c1d5858a3ad4f31cf/large-GettyImages-173245816-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Michael T. Byrne, DO]]></title><description><![CDATA[Michael T. Byrne, DO, is the cellular therapy program director at Tennessee Oncology, and medical director for cellular therapy at OneOncology.]]></description><link>https://www.oncologynewscentral.com/contributor/michael-t-byrne</link><guid isPermaLink="true">https://www.oncologynewscentral.com/contributor/michael-t-byrne</guid><pubDate>Tue, 12 May 2026 10:01:51 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/321yiThdiGeda4tqGxY6vc/cbc70676912fb95caccf608c130650c6/large-Byrne-Michael-1x1.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Adam Kittai, MD]]></title><description><![CDATA[Adam Kittai, MD, is the director of the CLL Program and an associate professor at NYU Langone Health’s Perlmutter Cancer Center. ]]></description><link>https://www.oncologynewscentral.com/contributor/adam-kittai</link><guid isPermaLink="true">https://www.oncologynewscentral.com/contributor/adam-kittai</guid><pubDate>Tue, 12 May 2026 09:56:30 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/2fOxwDLtB3qnanDzMxEL9g/024ea6697470804aedfd7796afcc5ea1/large-Kittai-1x1.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Katie Alexander, MSN, APRN-CNP, AOCNP]]></title><description><![CDATA[Katie Alexander, MSN, APRN-CNP, AOCNP, is a nurse practitioner at the Zangmeister Cancer Center in Columbus, Ohio, with active memberships in the American Cannabis Nurses Association and the American Association of Nurse Practitioners. She is passionate about advocating for the healthcare and cancer needs of the LGBTQAI population.]]></description><link>https://www.oncologynewscentral.com/contributor/katie-alexander</link><guid isPermaLink="true">https://www.oncologynewscentral.com/contributor/katie-alexander</guid><pubDate>Tue, 12 May 2026 09:50:09 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/53JaJLfybRRVcvwjNCbOmU/77b864d1e0c01f94568d8a696bf8b0fd/large-Katie-Alexandrer-1x1.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Challenging Clinical Case: A Grandfather With CLL]]></title><description><![CDATA[A 72-year-old grandfather with CLL experiences adverse events while receiving treatment with ibrutinib (Imbruvica). Can you correctly answer all five questions about this case?]]></description><link>https://www.oncologynewscentral.com/cll/challenging-clinical-case-a-grandfather-with-cll-and-treatment-complications</link><guid isPermaLink="true">https://www.oncologynewscentral.com/cll/challenging-clinical-case-a-grandfather-with-cll-and-treatment-complications</guid><pubDate>Mon, 11 May 2026 16:30:13 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/6lJ0zDIOg20M4gzR2uwxpC/ebc78f4ad178f76a05a836b7b02122a5/large-GettyImages-1190863700-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Toxicity and Workflow in NSCLC Care]]></title><description><![CDATA[Experts discuss toxicities tied to the MARIPOSA regimen, team-based care, EMR tools, and how subq therapies reduce time burden in NSCLC clinics.]]></description><link>https://www.oncologynewscentral.com/video/lung-cancer/oncology-is-nothing-but-a-team-effort-managing-toxicity-and-workflows-in-nsclc-patient-care</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/lung-cancer/oncology-is-nothing-but-a-team-effort-managing-toxicity-and-workflows-in-nsclc-patient-care</guid><pubDate>Mon, 11 May 2026 15:32:09 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/6nDS7SlZ7ERmA6H3NadWu2/a6ef51cd7000d8bafb6d1f4098766c98/large-Roundtable3.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[EGFRm NSCLC: Treatment for Brain Mets]]></title><description><![CDATA[Experts review brain mets management and emerging EGFR+ therapies, including TKIs, ADCs, and ctDNA insights.]]></description><link>https://www.oncologynewscentral.com/video/lung-cancer/managing-brain-mets-in-egfrm-nsclc-evolving-treatment-strategies</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/lung-cancer/managing-brain-mets-in-egfrm-nsclc-evolving-treatment-strategies</guid><pubDate>Mon, 11 May 2026 15:30:55 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/1GEZbHgWstbBjFZwcgre9q/7a6d9a0dab21f7e003b09306db40ede2/large-Roundtable5.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[EGFRm NSCLC: How Much Therapy Is Enough?]]></title><description><![CDATA[Experts discuss frontline treatment in EGFR-mutant NSCLC, including combination versus monotherapy, key trial data, and how to guide patient-centered decisions.]]></description><link>https://www.oncologynewscentral.com/video/lung-cancer/egfr-positive-nsclc-how-much-combination-therapy-is-adequate</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/lung-cancer/egfr-positive-nsclc-how-much-combination-therapy-is-adequate</guid><pubDate>Mon, 11 May 2026 15:29:36 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/3qVNc2tcAJqvZtt64euTI8/8763c3df604c494fed1bd764a9670fd0/large-Devarakonda-Herbst-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Tackling Community Oncology’s Biggest Issues]]></title><description><![CDATA[From administrative challenges to policy concerns, the challenges facing community oncology are “too many to count,” says Ted Okon, executive director of the Community Oncology Alliance.]]></description><link>https://www.oncologynewscentral.com/video/oncology/tackling-community-oncologys-biggest-issues</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/oncology/tackling-community-oncologys-biggest-issues</guid><pubDate>Mon, 11 May 2026 12:23:42 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/2udJxkEc3mx01tb6qkVUKE/87316d7955b90c4ed9b16dd783b6b865/large-Okon-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[“This Is a Crisis”: Reimbursement Cuts Hit Oncology]]></title><description><![CDATA[When it comes to the effect of recent reimbursement changes on radiation oncology, “This is a crisis. I’m going to be honest, it’s a crisis,” said Casey Chollet-Lipscomb, MD.]]></description><link>https://www.oncologynewscentral.com/video/oncology/this-is-a-crisis-reimbursement-cuts-hit-oncology</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/oncology/this-is-a-crisis-reimbursement-cuts-hit-oncology</guid><pubDate>Mon, 11 May 2026 10:51:51 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/3aCpjBErtn6C9rAgk2xa1Q/a6c11b7f7d61cae51156351d0ab3b544/large-Chollet-Lipscomb-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[FDA Approves Bispecific for Bile Duct Cancer]]></title><description><![CDATA[The FDA approved zenocutuzumab-zbco (Bizengri) for adults with advanced, unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma.]]></description><link>https://www.oncologynewscentral.com/drugs/info/fda-approves-bispecific-for-advanced-bile-duct-cancer</link><guid isPermaLink="true">https://www.oncologynewscentral.com/drugs/info/fda-approves-bispecific-for-advanced-bile-duct-cancer</guid><pubDate>Mon, 11 May 2026 10:15:24 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/6KM90rIxdkTtghKLjQnrxb/53d71f1f5e3ac318a13051333d016202/large-AdobeStock_470777235-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Bladder Cancer News to Watch for at AUA 2026]]></title><description><![CDATA[Experts are looking forward to noteworthy data from gene and immunotherapy trials in high-risk bladder cancer at the 2026 American Urological Association Annual Meeting.]]></description><link>https://www.oncologynewscentral.com/bladder-cancer/what-to-watch-for-at-the-american-urological-association-annual-meeting</link><guid isPermaLink="true">https://www.oncologynewscentral.com/bladder-cancer/what-to-watch-for-at-the-american-urological-association-annual-meeting</guid><pubDate>Fri, 08 May 2026 18:22:30 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/49UPA8DlQvaPNapztnwf6x/97ec4bc33fd0d2a7223320302875aedf/large-AdobeStock_288223056-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Imatinib: The Pill That Changed Cancer Care]]></title><description><![CDATA[Brian Druker, MD, developed imatinib while treating patients with CML who needed it most. His drive to bring it to trials still defines modern cancer care.]]></description><link>https://www.oncologynewscentral.com/experience/the-pill-that-changed-cancer-care</link><guid isPermaLink="true">https://www.oncologynewscentral.com/experience/the-pill-that-changed-cancer-care</guid><pubDate>Fri, 08 May 2026 15:20:37 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/1x0FvFCx75A7y7HoVikDsk/8fe7f916e1878371c02f8c41b421745b/Druker-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Community Oncology Is “a Little Bit on the Sidelines”]]></title><description><![CDATA[When it comes to community oncology’s adoption of new technology and other key advances, “we are a little bit on the sidelines,” says Johnetta Blakely, MD, MS, MMHC.]]></description><link>https://www.oncologynewscentral.com/video/oncology/community-oncology-is-a-little-bit-on-the-sidelines-when-it-comes-to-key-advances</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/oncology/community-oncology-is-a-little-bit-on-the-sidelines-when-it-comes-to-key-advances</guid><pubDate>Thu, 07 May 2026 10:10:55 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/6Q7NkgGOAnp2SVwpKyq27q/feb78f4832c4ba0e950b17b9ccea6bc1/large-Blakely-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Report Answers Big Question in Community Oncology]]></title><description><![CDATA[A first-of-its-kind study recently showed that patients with metastatic cancer had longer survival compared with national benchmarks. Stephen “Fred” Divers, MD, describes key findings.]]></description><link>https://www.oncologynewscentral.com/video/oncology/first-of-its-kind-report-answers-big-question-in-community-oncology</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/oncology/first-of-its-kind-report-answers-big-question-in-community-oncology</guid><pubDate>Wed, 06 May 2026 19:01:20 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/13GWgfJsmCo1u77azJTZee/d6ded4c90b7dc8cb44d5e9375fb412d2/Divers-Screenshot-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[HYPO-RT-PC Prostate Cancer Trial: Research Recap]]></title><description><![CDATA[The phase 3 HYPO-RT-PC trial showed that ultra-hypofractionated radiotherapy matches conventional fractionation for failure-free survival in localized prostate cancer.]]></description><link>https://www.oncologynewscentral.com/prostate-cancer/ultra-hypofractionated-radiotherapy-matches-conventional-factionation-in-prostate-cancer-research-recap</link><guid isPermaLink="true">https://www.oncologynewscentral.com/prostate-cancer/ultra-hypofractionated-radiotherapy-matches-conventional-factionation-in-prostate-cancer-research-recap</guid><pubDate>Wed, 06 May 2026 13:41:31 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/4WnnkxZtOZqDaXqGDO3tHv/4a8baceadbc15475da91d62abda5a008/large-AdobeStock_613312540-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Guideline Questions Emerge in Ovarian Cancer]]></title><description><![CDATA[ESMO’s recently published express update to its clinical guidelines for epithelial ovarian cancer are “already out of date,” according to an American expert.]]></description><link>https://www.oncologynewscentral.com/ovarian-cancer/rapidly-changing-landscape-in-ovarian-cancer-raises-questions-about-newly-updated-guidelines</link><guid isPermaLink="true">https://www.oncologynewscentral.com/ovarian-cancer/rapidly-changing-landscape-in-ovarian-cancer-raises-questions-about-newly-updated-guidelines</guid><pubDate>Wed, 06 May 2026 11:15:33 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/4vyQyVBv2FMxOrgZmVkZQT/689c989461ba56dc030d74a79ac60c02/large-AdobeStock_455677417-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Hot Topics to Watch for at the ONS Annual Congress]]></title><description><![CDATA[The 51st Annual Oncology Nursing Society Congress, held May 13–17, will include sessions on hot topics from nurse bullying to oncologic emergencies.]]></description><link>https://www.oncologynewscentral.com/oncology/what-to-watch-for-at-the-oncology-nursing-society-annual-congress</link><guid isPermaLink="true">https://www.oncologynewscentral.com/oncology/what-to-watch-for-at-the-oncology-nursing-society-annual-congress</guid><pubDate>Wed, 06 May 2026 10:41:50 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/2RwTHAVFTIiKN18Z6MKY5E/adf2785d0f50fbf3f8c83115a0408a3b/large-GettyImages-2159129288-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[“Major Milestone”: FDA Acts on Pancreatic Cancer Drug]]></title><description><![CDATA[The FDA approved an expanded access treatment protocol for daraxonrasib in patients with previously treated metastatic pancreatic cancer.]]></description><link>https://www.oncologynewscentral.com/drugs/info/fdas-action-on-pancreatic-cancer-drug-marks-major-milestone</link><guid isPermaLink="true">https://www.oncologynewscentral.com/drugs/info/fdas-action-on-pancreatic-cancer-drug-marks-major-milestone</guid><pubDate>Wed, 06 May 2026 10:20:47 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/5MnktNrW7aVgwEnYcrxfsy/adeb18ef6ca6bd625cd73ebec1a0a6dd/large-GettyImages-2043234790-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[“The Dying Breed of Community Oncology” Needs Defenders]]></title><description><![CDATA[Now, more than ever, it is crucial to focus on “bringing awareness to the dying breed of community oncology,” argues Harsha Vyas, MD.]]></description><link>https://www.oncologynewscentral.com/video/business-and-policy/the-dying-breed-of-community-oncology-needs-defenders</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/business-and-policy/the-dying-breed-of-community-oncology-needs-defenders</guid><pubDate>Tue, 05 May 2026 12:23:31 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/5yRVwAZE9VwHw01VfkEPcV/f0be86414fbbc53bbc3978415a3b2203/large-Harsha_Vyas-screenshot-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[News Scan]]></title><description><![CDATA[A quick review of oncology headlines that matter most.]]></description><link>https://www.oncologynewscentral.com/news-scan</link><guid isPermaLink="true">https://www.oncologynewscentral.com/news-scan</guid><pubDate>Mon, 04 May 2026 16:36:15 GMT</pubDate></item><item><title><![CDATA[Cancer Drugs Fast-Tracked by the FDA in April 2026]]></title><description><![CDATA[In April, the FDA granted fast track designations to various oncology drugs. Here are some of the key highlights.]]></description><link>https://www.oncologynewscentral.com/drugs/info/oncology-drugs-fast-tracked-by-the-fda-in-april-2026</link><guid isPermaLink="true">https://www.oncologynewscentral.com/drugs/info/oncology-drugs-fast-tracked-by-the-fda-in-april-2026</guid><pubDate>Mon, 04 May 2026 13:08:55 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/c4LPfJH8jsf0fOGJlwmLp/bb9029a9f72b220dbbe515a924f6a9f8/large-AdobeStock_1852513227_3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item><item><title><![CDATA[Community Oncology Faces “A Practice-Ending Event”]]></title><description><![CDATA[Reimbursement challenges may represent “a practice-ending event” for community oncology practices, says Nicholas Ferreyros, a managing director at the Community Oncology Alliance.]]></description><link>https://www.oncologynewscentral.com/video/business-and-policy/community-oncology-faces-a-practice-ending-event</link><guid isPermaLink="true">https://www.oncologynewscentral.com/video/business-and-policy/community-oncology-faces-a-practice-ending-event</guid><pubDate>Mon, 04 May 2026 10:53:20 GMT</pubDate><enclosure url="https://images.ctfassets.net/tgf4i61m32yj/1wPjpkPuCaJnmpFJazVmjO/722022ba3cd4d9b4cee78a47a14ca835/large-Ferryros-3000x2000.jpg?fm=avif" length="620" type="image/jpeg"/></item></channel></rss>